Navigation Links
Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Date:6/28/2011

80 mcg/dayMean baseline HbA1c (%)

7.8

7.8

8.1

7.9Mean week 48 HbA1c (%)

6.8

6.8

6.6

6.5Mean HbA1c change at week 48

1.0

1.0

1.5

1.4Mean weight change at week 48 (lbs)

-6

-10.8

-7.7

-7.9Based on the consistent results observed at the week 24 study endpoint and the week 48 extension, a starting dose of ITCA 650 20 mcg/day for weeks 1 – 12 followed by transition to ITCA 650 60 mcg/day appears to provide the most substantial incremental reductions in HbA1c, FPG and body weight with the most favorable tolerability profile.

Throughout the extended treatment duration of the study, there were no treatment discontinuations due to nausea.  Numeric improvements were observed in measures of BP and lipids at weeks 24 and 48 compared to baseline.

"Testing novel therapies over longer treatment durations is very important to confirm sustained efficacy effects, safety and tolerability," said Julio Rosenstock, MD, ITCA 650 phase 2 study principal investigator.  These encouraging findings warrant further investigation of the optimized dose regimen of ITCA 650 20 - 60 mcg/day in large phase 3 studies and using longer duration devices."  

Patient Satisfaction SurveyA treatment satisfaction questionnaire was administered to patients before the study and at study weeks 8 and 20.  Results of the week 8 assessment suggested a higher level of satisfaction among patients receiving ITCA 650 20 mcg/day or ITCA 650 40 mcg/day compared with patients self-injecting exenatide twice daily.  Results of the week 20 assessment showed a substantial improvement in treatment satisfaction among patients switching from exenatide injection to ITCA 650 and that the substantial improvement observed among patients initially randomized to ITCA 650 was maintained after transition to higher doses of ITCA 650.

I
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
9. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
10. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
11. TGen and PBS-Bio presents 2 abstracts at AACR conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... top line data from a Phase 2 clinical trial ... of Influenza-Like Illness (ILI) caused by all types and ... strains. In a double-blind, placebo-controlled, Phase 2 trial of ... DAS181 resulted in a significant reduction in patients, influenza ...
... (July 1, 2011) After Fukushima, it is now imperative ... from cradle to grave. If nuclear waste management is not ... will reject nuclear power as an energy choice, according to ... Atomic Scientists , published by SAGE. According to Allison ...
... just fifteen minutes to analyze a sample suspected of ... The technology amplifies any anthrax DNA present in the ... microscopic cells of the deadly bacteria Bacillus anthracis. ... lethal microbe that might be used intentionally to infect ...
Cached Biology Technology:NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 2NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 3NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 4Nuclear waste requires cradle-to-grave strategy 2Nuclear waste requires cradle-to-grave strategy 3Nano detector for deadly anthrax 2
(Date:4/17/2014)... eight years ago, Katia Silvera , a postdoctoral scholar ... on a field trip in a mountainous area in central ... seen before. , Unable to identify it, they contacted German ... out to be an unnamed species. So Carnevali recently named ... is the genus name, comprising about 40 species in the ...
(Date:4/17/2014)... devastate honeybees in Europe, Asia and the United States ... to be impacting native honeybee populations at this time, ... pests include including Nosema microsporidia and ... be resilient to these invasive pests, which suggests to ... Europe, Asia and the United States currently are not ...
(Date:4/17/2014)... implicated in many serious conditions such as heart disease, ... for drug therapies. Unfortunately, there is still much scientists ... provides fresh and unexpected insight into the structure of ... β-subunit molecules - which are responsible for ,fine-tuning, the ... the most recent edition of the Journal of ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2
... A University at Buffalo volcanologist, an expert in volcanic ash ... stream -- the area in the atmosphere that pilots prefer ... most likely to be impacted by plumes from volcanic ash. ... of the foremost experts on volcanic plumes and their effect ...
... species of dinosaur with a softball-sized lump of solid bone ... in the April issue of the journal Cretaceous Research ... as big as a medium-sized dog that lived 70 to ... lead author of the paper. The team discovered two skull ...
... take long for Binghamton University educational historian Adam Laats to ... in Wisconsin. "I was amazed at how nave I ... said Laats, now an assistant professor in Binghamton,s School of ... what was being taught in the classroom. Things I thought ...
Cached Biology News:Volcanic ash research shows how plumes end up in the jet stream 2New bony-skulled dinosaur species discovered in Texas 2Educational historian looks at origins of the culture wars 2Educational historian looks at origins of the culture wars 3
... Thermo Electron's most advanced personal gradient option ... use sophisticated onboard software and a large ... offer performance, accuracy and simplicity in thermal ... customer driven features built up on years ...
Control primers and template for 5kb and 15 kb products....
Carrier Serum...
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
Biology Products: